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Introduction
Juvenile dermatomyositis (JDM) is a multisystem disease of uncertain 
origin that is defined by chronic inflammation of striated muscle and skin 
in children less than 16 years of age(1). Perifascicular atrophy is the (1)
typical muscular and vascular histologic outcome of JDM. Amyopathic 
dermatomyositis is an uncommon variant of JDM, characterized by the 
hallmark cutaneous features of dermatomyositis for at least 6 months 
without clinical or laboratory evidence of muscle disease. Cases of 
dermatomyositis with absent skin findings have been reported and are 
referred to as adermatopathic dermatomyositis (2). Herein, we present 
the findings of a patient with adermatopathic JDM.
Case Presentation
A 10-year-old girl presented with had upper limb pain from shoulder to 
wrist and lower limb pain from hip to knee that has lasted three months. 
She had progressive proximal limb weakness to the extent that she could 
barely walk five steps and was unable to comb her hair. She also was 
able to feed herself, but she gets tired very quickly and had a history 
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Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory 
disease, which usually presents with skin rashes along with muscle 
weakness. We report a case of JDM in a 10- year-old girl with no skin 
manifestations 
presenting with progressive muscle weakness and fatigue. Further 
laboratory investigations, along with a muscle biopsy, confirmed 
the diagnosis of adermatopathic JDM. The patient was treated 
with intravenous immunoglobulin, corticosteroids, methotrexate, 
hydroxychloroquine, pamidronate, and rituximab.
Following treatment, patients’ symptoms subsided, and she gained 
normal muscular strength over a year.
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of remittent fever. The patient had no complaints 
of constipation, diarrhea, or any abdominal pain. 
On initial assessment, she was afebrile, and the 
examinations showed diffused tender, warm 
muscles with proximal limb weakness, and 
medical research council (MRC) scale for muscle 
strength grade 2 for upper and lower limbs. Her 
shoulder had limited passive range of motion due 
to pain, and her knees and hip joints were tender. 
Deep tendon reflexes were present and normal. 
The Gottron’s papules and heliotrope rashes 
were absent, and no skin involvement was found. 
Fingers and nails were found to be normal. 
Further investigations yielded the following 
results: Creatine Phosphokinase (CPK): 3047 
U/L, Alanine Aminotransferase (ALT): 81 U/L, 
Aspartate Aminotransferase (AST): 173 U/L, 
Lactate Dehydrogenase (LDH): 1271 U/L, 
Erythrocyte Sedimentation Rate (ESR): 16 mm/
hr, Anti-nucleotide Antibody (ANA): 0.4, and 
25-hydroxycholecalciferol (VitD): 8 ng/mL. Urine 
analysis showed leukocyturia, urine culture showed 
30000 30,000 colonies of two types, and the results 
were negative for C-Reactive Protein (CRP), 
Rheumatoid Factor (RF), 2-Mercapthoethanol 
(2ME), and wright. Electromyography and Nerve 
Conduction Velocity (EMG/NCV) findings were 
consistent with a myogenic process; therefore, a 
muscle biopsy was performed. Deltoid muscle 
biopsy was performed, and the specimen was 
sent to be frozen in Isopentane cooled in liquid 
nitrogen. A panel of histology and histochemistry 
studies revealed a perifascicular atrophy 
pattern with the presence of atrophic basophilic 
degenerative/regenerative fibers at the periphery 
of the fascicles containing internalized nuclei 
(Figure 1a). Perimysial perivascular infiltration 
of lymphocytes was also noted (Figure 1b). Based 
on these pathognomonic findings associated with 
the patient’s phenotype, the diagnosis of JDM was 
made.
The patient was hospitalized to receive six courses 
of treatment. Intravenous Immunoglobulin (IVIG) 
therapy was initiated (2 gr/Kg per session) and was 
monthly repeated for 6 months. Methylprednisolone 
(30 mg/Kg) was also administered intravenously 
for 3 consequent days. Treatment followed by oral 
Prednisolone, Methotrexate, Hydroxychloroquine, 
Folic Acid, Calcium, and Vitamin D3 Supplements 
as maintenance therapy. The treatment did not 
change her distal upper and lower limb weakness; 
however, proximal upper limb weakness was 
resolved. After six months of treatment using IVIG 
and steroid, the lower limb weakness worsened 
(MRC grade 4), and areflexia of patellar tendon was 
observed. No signs of lower limb polyneuropathies 
were found on further neurological assessment.
Our patient showed signs of Cushing’s syndrome (purple 
striae, moon face, osteopenia, and fragile skin) two 
months after initiating treatment with corticosteroids, 
and she complained of lumbosacral pain.
Therefore, treatment with Rituximab (500 mg/
m2) was started followed by other complementary 
doses. Her condition was markedly improved, 
and she was discharged with the aforementioned 
routine prescriptions to be followed up.
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Figure 1a. Multiple foci of perivascular perimysial chronic inflammation (H&E stain *40)
Figure 1b. Typical perifascicular atrophy pattern (H&E stain*400)
Discussion
Dermatomyositis is a chronic inflammation of unknown 
origin involving the musculoskeletal system. Chronic 
Idiopathic Inflammatory Myopathies (IIMs) in children 
are a heterogeneous group of disorders. Although many 
affected children have muscle and skin abnormalities 
similar to JDM, it can be diagnosed by the five criteria 
developed by Bohan and Peter (4, 3). Diagnosis of 
JDM often requires the presence of the pathognomonic 
rashes (Heliotrope rash or Gottron papules over 
the extensor surfaces) and two other criteria (4, 3); 
however, due to the cases of dermatomyositis in adults 
without skin involvement (2), a different subtype, 
adermatopathic dermatomyositis, has been postulated. 
It is defined by the absence of skin rashes along with 
myositis plus either perifascicular atrophy at muscle 
biopsy or pathognomonic rashes emerging in the 
follow-up or calcinosis in dermatomyositis (5). To our 
knowledge, there is no reported case of adermatopathic 
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dermatomyositis in childhood. Rituximab has been 
shown effective against severe/refractory cases of JDM 
therefore, it was used to treat the patient and showed 
favorable outcomes. 
In conclusion
In our experience, treatment with intravenous 
immunoglobulin injections, methotrexate, 
hydroxychloroquine, and corticosteroids showed 
no satisfactory improvement in patient with 
adermatopathic dermatomyositis. However, using 
the biologic Rituximab was effective to control 
and treat the disorder.
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